AI-generated summary
The authors prospectively treated 35 people with refractory melasma using a Q-switched Nd:YAG laser combined with 7% alpha arbutin solution over six months. At six months, 30% had excellent clearance and 36.7% had good clearance, with mild, transient side effects and some hypo-pigmentation and recurrence reported. The authors describe the combination as effective and well tolerated.
- Participants
- 35
- Who or what was studied
- People with refractory melasma
- Limits stated in the abstract
- The abstract describes a single prospective study of 35 cases without a control group, and it does not report a wavelength for the laser.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.